According to the company the dose counter is designed to help asthma patients, as well as their caregivers to keep track of the number of doses remaining in the canister.
The new QVAR with a dose counter will be commercially available later in 2014.
QVAR is an inhaled corticosteroid (ICS) indicated as a twice-daily treatment for long-term asthma control.
It is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or remove the need for systemic corticosteroids.
Teva senior vice president of Global Respiratory Research and Development Tushar Shah said bringing QVAR with a dose counter to market reaffirms the company’s commitment to addressing unmet needs by providing high-quality and innovative solutions to patients.
"Adding to our rich heritage within the respiratory space, we are pleased that all Teva Respiratory brands in the US will soon include a dose counter, which will help patients and caregivers track how many doses of their medication remain," Shah said.
The company said that adherence to daily control medications, like QVAR, is important because when asthma is well controlled, fewer asthma attacks may occur.